Pre-MEASURE: <i>FLT3</i> -ITD and mutated <i>NPM1</i> measurable residual disease before allogeneic transplant in adults with AML in first remission
Laura W. Dillon(Institute of Cancer Research), Christopher S. Hourigan(National Heart Lung and Blood Institute), Steven M. Devine(National Marrow Donor Program), Kristin Page(Medical College of Wisconsin), Antonio Jiménez(University of Miami), Zoë C. Wong(National Institutes of Health), Devdeep Mukherjee(National Institutes of Health), Alan Howard(National Marrow Donor Program), Firas El Chaer(The University of Texas MD Anderson Cancer Center), Georgia Andrew(National Institutes of Health), Gege Gui(Johns Hopkins University), Wael Saber(Medical College of Wisconsin), Stephen R. Spellman(National Marrow Donor Program), Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Daniel J. Weisdorf(University of Minnesota), Karen Chen(North Carolina State University), Mark R. Litzow(Mayo Clinic in Arizona), Jeffery J. Auletta(Nationwide Children's Hospital), Scott L. Zeger(Johns Hopkins University), Marcos J.G. De Lima(The Ohio State University), Niveditha Ravindra(National Institutes of Health)
Cited by 1
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k